Updating the DrugPatentWatch Biologics Module
Before the passage of the Biologic Patent Transparency Act DrugPatentWatch’s biologic patent data was cited as a reason why the […]
Before the passage of the Biologic Patent Transparency Act DrugPatentWatch’s biologic patent data was cited as a reason why the […]
This paper was originally published by Andreas H. Göller, Lara Kuhnke, Floriane Montanari, Anne Bonin, Sebastian Schneckener, Antoniuster Laak, Jörg
This paper was originally published by Md. Imtiaz Hasan et al in Journal of Biosciences and Medicines under a Creative Commons
When it comes to pricing generic drugs, there are a number of factors that come into play. In countries without
Want insights into the biggest revenue-changing events? ➤ Get Your Certificate Today By tracking patent expirations, patent litigation, generic and
Free Course in Generic and Branded Drug Lifecycle Management Read Post »
How Much Time Are You Wasting on Manual, Repetitive Tasks? Stop wasting time on repetitive reports: Contact us Are your
Stop paying your staff to make repetitive reports Read Post »
This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA Read Post »
This article was first published by Elinevan Overbeeke, Sissel Michelsen, Mondher Toumi, Hilde Stevens, Mark Trusheim, Isabelle Huys, and StevenSimoens
This article was originally published by Abdrhman Mahmoud Gamil in World Journal of Advanced Research and Reviews, 2020, 08(03), 337–349